RCT: In patients with untreated advanced melanoma, treatment with Relatlimab plus Nivolumab was associated with increased median progression-free survival compared with Nivolumab alone (10.1 months vs. 4.6 months).

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma – University of Texas M. D. Anderson Cancer Center

Commentary on Twitter

The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to PFS than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. https://t.co/idtOgksg74 pic.twitter.com/vx1W9O4Dh6

— NEJM (@NEJM) January 5, 2022